19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD

Phase 3positiveOlatorepatidePositive

AI Analysis

Summary

Hansoh Pharma presented Phase 3 data for Olatorepatide, a dual-biased GLP-1/GIP agonist, showing 19.3% weight loss at Week 48 at the EASD Annual Meeting in Milan.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

19.3% weight loss at Week 48

Importance:7/10

Sentiment:

0.80

Phase 3weight lossGLP-1/GIP agonistdual-biasedEASD conferencedata presentation

Related Companies

$HNPHY

Read the original article

Published by PR Newswire Biotech on October 2, 2026 4:00 AM

Read Original